For research and educational purposes only. Not medical advice.

PEG-MGF Reference

Educational, not medical advice reference for PEG-MGF: Growth Factor, Recovery; regulatory status, evidence posture, source review, and schedule notes. Also…

Reference summary

Published work is preclinical, mostly rodent and cell-culture studies of muscle-progenitor activation. There is no published human clinical program for PEG-MGF as a research peptide.

Categories
Growth Factor, Recovery
Aliases
Mechano growth factor, IGF-1Ec splice variant, Pegylated MGF
Evidence posture
preclinical — WADA-prohibited. No published human clinical program for PEG-MGF. Hypoglycemia, tissue-overgrowth, and anti-doping sanction are the principal documented risks, similar to the IGF-1 family.
Regulatory status
No FDA-approved PEG-MGF drug label. PEG-MGF is the pegylated form of the IGF-1 Ec-splice variant (mechano growth factor). WADA prohibits IGF-1 and its analogs under category S2 at all times.
Content review status
research reference

Selected public sources